SAN DIEGO, Jan. 3, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 29th
Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 10, 2011 at 4:30 p.m. ET / 1:30 p.m.
PT. Daniel M.
Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will provide a corporate overview.
The presentation and break-out session will be webcast through
the "Investors" section of Amylin's corporate website at
www.amylin.com, and a recording will be made available following
the event. To access the live webcast, please log on to Amylin's
site approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.